Drug Trial Radar · NCT02130557
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Last checked: Nov 20, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
536
Actual
Start
Jul 15, 2014
Primary completion
Aug 11, 2016
Study completion Apr 17, 2020
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 5, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
Conditions
- Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
Interventions
BosutinibDrug
Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
ImatinibDrug
Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial. Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Major Molecular Response (MMR) at Month 12Time frame: Month 12
Locations
189 sites in 26 countries. Site status is shown where the registry gives one.
Pacific Cancer Medical Center, Inc.
Anaheim, California
Emory University Hospital
Atlanta, Georgia
The Emory Clinic
Atlanta, Georgia
Winship Cancer Institute, Emory University
Atlanta, Georgia
Kaiser Permanente Hawaii
Honolulu, Hawaii
Saint Alphonsus Regional Medical Center, Cancer Care Center
Boise, Idaho
Saint Alphonsus Regional Medical Center
Boise, Idaho
Saint Alphonsus Caldwell Cancer Care Center
Caldwell, Idaho
Saint Alphonsus Medical Center Nampa
Nampa, Idaho
University of Illinois Cancer Center
Chicago, Illinois
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana
PHARMACY Department Franciscan St. Francis Health ATTN:Jill Leslie, Pharm D
Indianapolis, Indiana
Cancer Center of Acadiana at Lafayette General Medical Center
Lafayette, Louisiana
Lafayette General Medical Center
Lafayette, Louisiana
LSU Health Sciences Center-Shreveport
Shreveport, Louisiana
University Health Shreveport
Shreveport, Louisiana
Rcca Md Llc
Bethesda, Maryland
University of Massachusetts Memorial Medical Center, ONC/Research Pharmacy
Worcester, Massachusetts
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
St. Joseph Mercy Hospital - Inpatient Pharmacy
Ann Arbor, Michigan
St. Joseph Mercy Hospital
Ann Arbor, Michigan
St. Joseph Mercy-Brighton
Brighton, Michigan
St. Joseph Mercy-Canton
Canton, Michigan
Chelsea Community Hospital
Chelsea, Michigan
St. John Hospital&Medical Center
Detroit, Michigan
St. John Hospital&Medical Center-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan
Van Elslander Cancer Center, Pharmacy
Grosse Pointe Woods, Michigan
Minnesota Oncology Hematology, PA
Edina, Minnesota
Park Nicollet Frauenshuh Cancer center
Saint Louis Park, Minnesota
Lakeview Hospital
Stillwater, Minnesota
North Mississippi Medical Center Hematology and Oncology Clinic
Tupelo, Mississippi
Nebraska Methodist Hospital
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
NYU Winthrop Hospital - Oncology / Hematology department
Mineola, New York
NYU Winthrop Hospital - Pharmacy Department
Mineola, New York
Beth Israel Medical Center
New York, New York
University of Rochester Investigational Drug Pharmacy
Rochester, New York
Showing 40 of 189 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.